DLA Piper is dedicated to helping forward-thinking businesses address today’s challenges and shape a better world. With a bold and dynamic culture, it emphasizes excellence in client relationships, community service, and people development. The firm fosters creativity, strategic thinking, inclusivity, and collaboration to exceed expectations. Recognizing the importance of environmental, social, and governance (ESG) issues, the firm actively supports clients in transitioning to sustainable futures. It promotes purpose, transparency, and sustainability within its own governance and operations, ensuring its people are equipped to deliver exceptional results for clients while making a positive societal impact.
In the ongoing CRISPR patent battle, after four days of oral arguments, it was announced today that the European Patent Office's (EPO) Technical Board of Appeal (Board)
In the ongoing CRISPR patent battle, after four days of oral
arguments, it was announced today that the European Patent
Office's (EPO) Technical Board of Appeal (Board) upheld the
earlier EPO Opposition Division ruling from January 2018, stating
that Broad Institute's European patent EP2771468 is not novel
and therefore fully revoked.
The Board confirmed the prior decision, finding that all claims
of the Broad Institute's patent for gene editing were invalid
because the Broad Institute was not entitled to its earliest
priority dates and therefore the claims lacked novelty in light of
prior art. Thus, all claims of the Broad Institute's patent
remain fully revoked and the Opposition Division's decision to
revoke the patent is now final.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
